1.	Phase III Randomized Study of Fulvestrant With Versus Without Anastrozole Versus Exemestane Alone in Postmenopausal Women With Estrogen Receptor and/or Progesterone Receptor Positive Locally Advanced or Metastatic Breast Cancer That Relapsed or Progressed During Prior Treatment With Nonsteroidal Aromatase Inhibitors Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422
2.	Phase III Randomized Study of Fulvestrant With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage III or IV Hormone Receptor-Positive Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40302, NCT00390455
3.	Fulvestrant (Faslodex) + Anastrozol (Arimidex) vs Anastrozol Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GEICAM/2006-10, NCT00543127
4.	Phase III Randomized Study of Fulvestrant With or Without Lapatinib Tosylate and/or Aromatase Inhibitor Therapy in Postmenopausal Women With Metastatic Breast Cancer That Progressed After Prior Aromatase Inhibitor Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GIM-GIM8-OVER, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194
5.	Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) Phase: Phase III Type: Treatment Status: Active Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: 9238UK/0005, NCT00944918
6.	Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0336, NCT00903006
7.	Phase II Randomized Study of Erlotinib Hydrochloride With Versus Without Fulvestrant in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: NCI Protocol IDs: UCLA-0407058-01, NCT00100854
8.	Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OSU-0494, NCT00201864
9.	Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10736, H6Q-MC-S023, NCT00451555
10.	Fulvestrant in Hormone Refractory Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: PROS0010, 96025, NCT00476645, PROS0010, NCT00476645
11.	Phase II Trial of Capecitabine in Combination With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ALSSMBC0606, NCT00534417
12.	Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 to 55 Sponsor: Other Protocol IDs: UARK 2004-19, NCT00570258
13.	Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: H 20431, PACT 001, NCT00570323
14.	Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure Phase: Phase II Type: Treatment Status: Active Age: 45 and over Sponsor: Other Protocol IDs: 07-BRE-43-NP, NCT00570921
15.	Phase II Randomized Study of Neoadjuvant Anastrozole Versus Fulvestrant in Postmenopausal Women With Resectable Stage II or III Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: Postmenopausal Sponsor: Other, Pharmaceutical / Industry Protocol IDs: FNCLCC-CARMINA-02/0609, FNCLCC-CARMINA 02/0609 – NIMFEA, EU-20805, FNCLCC-NIMFEA, ZENECA-FNCLCC-CARMINA-02-0609, NCT00629616
16.	Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UCSD-060769, HRPP# 060769, NCT00592007
17.	Phase II Study of Salvage Therapy Comprising Sorafenib Tosylate and Fulvestrant in Patients With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer That Failed Prior Aromatase Inhibitor Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: OHSU-4318, 4318, BAYER-OHSU-4318, NCT00722072
18.	Pre-Operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: N08AFT, EudraCT; 2008-000644-13, NCT00738777
19.	ZACtima FASlodex Trial Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: D4200L00009, EUDRACT n° 2008-000579-12, NCT00752986
20.	Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA180-158, USOR 06-030, NCT00754325
21.	Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 45 and over Sponsor: Other Protocol IDs: OCOG-2008-ZAMBONEY, NCT00811369
22.	Positron Emission Tomography/Computerized Tomography (PET/CT) Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer Phase: Phase II Type: Diagnostic, Treatment Status: Approved-not yet active Age: 45 and over Sponsor: Other Protocol IDs: PET/CT Breast, PET/CT, Recurrent or metastatic, Breast Cancer, NCT00816582
23.	Phase II Randomized Study of Neoadjuvant Anastrozole Versus Fulvestrant in Postmenopausal Patients With Hormone-Sensitive Nonmetastatic Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 84 and under Sponsor: Other, Pharmaceutical / Industry Protocol IDs: IB-HORGEN, IB-IB2007-26, HORGEN, INCA-RECF0514, EUDRACT-2007-004216-31, ZENECA-IB-HORGEN, NCT00871858
24.	Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 11595, IRUSANAS0092, NCT00921115
25.	A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) Phase: Phase II Type: Treatment Status: Active Age: 45 to 85 Sponsor: Other Protocol IDs: FIDeS, NCT00927511